Original research
par
Acheson, Liam S. et al
Date de publication
2022
Géographie
Australia
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Yes
L’objectif
This study aimed to determine the feasibility and safety of a tapering dose of lisdexamfetamine for the treatment of acute methamphetamine (MA) withdrawal.
Constatations/points à retenir
A tapering dose regimen of lisdexamfetamine was safe and feasible for the treatment of acute methamphetamine withdrawal in an inpatient setting.
La conception ou méthodologie de recherche
Open-label, single-arm pilot study (n=10), in an inpatient drug and alcohol withdrawal unit assessing a tapering dose of oral lisdexamfetamine dimesylate commencing at 250 mg once daily, reducing by 50 mg per day to 50 mg on Day 5.
Mots clés
Stimulants
Withdrawal
Clinical guidance
